Doxycycline is a commonly prescribed medication for the management of acne vulgaris. Severe adverse reactions to this medication are uncommon. We describe an unusual case of a 20-year-old female who experienced a life-threatening hypersensitivity reaction, including fever, lymphadenopathy, hepatitis, nephritis and severe pneumonitis with respiratory failure following oral administration of doxycycline for facial acne.

1.
Pawin H, Chivot M, Beylot C, Faure M, Poli F, Revuz J, Dreno B: Living with acne. A study of adolescents’ personal experiences. Dermatology 2007;215:308–314.
2.
Akcam FZ, Aygun FO, Akkaya VB: DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J Infect 2006;53:e51–e53.
3.
Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123–129.
4.
Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258–265.
5.
Smilack JD: The tetracyclines. Mayo Clin Proc 1999;74:727–729.
6.
Shapiro LE, Knowles SR, Shear NH: Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224–1230.
7.
Knowles SR, Shapiro L, Shear NH: Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996;132:934–939.
8.
Toyoshima M, Sato A, Hayakawa H, Taniguchi M, Imokawa S, Chida K: A clinical study of minocycline-induced pneumonitis. Intern Med 1996;35:176–179.
9.
Curley RK, Verbov JL: Stevens-Johnson syndrome due to tetracyclines – a case report (doxycycline) and review of the literature. Clin Exp Dermatol 1987;12:124–125.
10.
Trueb RM, Burg G: Acute generalized exanthematous pustulosis due to doxycycline. Dermatology 1993;186:75–78.
11.
Cac N, Messingham MJ, Sniezek PJ, Walling HW: Stevens-Johnson syndrome induced by doxycycline. Cutis 2007;79:119–122.
12.
Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137:357–364.
13.
Saivin S, Houin G: Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355–366.
14.
Bocker R, Estler CJ, Weber A: Metabolism of doxycycline. Lancet 1982;2:1155.
15.
Lee AY, Kim MJ, Chey WY, Choi J, Kim BG: Genetic polymorphism of cytochrome p450 2c9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004;60:155–159.
16.
Ates NA, Tursen U, Tamer L, Kanik A, Derici E, Ercan B, Atik U: Glutathione s-transferase polymorphisms in patients with drug eruption. Arch Dermatol Res 2004;295:429–433.
17.
Ohtani T, Hiroi A, Sakurane M, Furukawa F: Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. Br J Dermatol 2003;148:1035–1039.
18.
Markel A: Allopurinol-induced dress syndrome. Isr Med Assoc J 2005;7:656–660.
19.
Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP: Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13–17.
20.
Muller P, Dubreil P, Mahe A, Lamaury I, Salzer B, Deloumeaux J, Strobel M: Drug hypersensitivity syndrome in a West-Indian population. Eur J Dermatol 2003;13:478–481.
21.
Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP: Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631–634.
22.
Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet 1999;353:2190–2194.
23.
Hamer HM, Morris HH: Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants. Cleve Clin J Med 1999;66:239–245.
24.
Turner RB, Kim CC, Streams BN, Culpepper K, Haynes HA: Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms. J Am Acad Dermatol 2004;50(suppl):S86–S89.
25.
Allam JP, Paus T, Reichel C, Bieber T, Novak N: DRESS syndrome associated with carbamazepine and phenytoin. Eur J Dermatol 2004;14:339–342.
26.
Tham SN, Kwok YK, Chan HL: Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996;132:1134–1135.
27.
Tigecycline (Tygacil). Obstet Gynecol 2006;107:178–180.
28.
Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323–327.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.